Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Adaptive Biotechnologies (NASDAQ:ADPT) had its price target increased by equities researchers at JPMorgan Chase & Co. from $20.00 to $21.00 in a report released on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 33.16% from the company’s previous close.

Several other research analysts have also issued reports on the stock. Piper Sandler set a $21.00 price target on shares of Adaptive Biotechnologies in a research note on Friday. Guggenheim raised their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, January 26th. TD Cowen reiterated a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday. Wall Street Zen downgraded Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Adaptive Biotechnologies presently has a consensus rating of “Moderate Buy” and an average price target of $17.56.

Adaptive Biotechnologies Stock Down 4.3%

ADPT opened at $15.77 on Friday. Adaptive Biotechnologies has a 52 week low of $6.26 and a 52 week high of $20.76. The stock has a market cap of $2.41 billion, a PE ratio of -39.42 and a beta of 2.18. The business has a 50 day moving average of $17.03 and a 200-day moving average of $15.23.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. The business had revenue of $71.68 million during the quarter, compared to the consensus estimate of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 48.73% and a negative net margin of 21.48%.The firm’s quarterly revenue was up 51.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.23) earnings per share. Equities analysts anticipate that Adaptive Biotechnologies will post -0.92 EPS for the current year.

Insider Activity

In related news, insider Francis Lo sold 79,590 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $17.73, for a total value of $1,411,130.70. Following the completion of the transaction, the insider directly owned 315,978 shares in the company, valued at $5,602,289.94. The trade was a 20.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Harlan S. Robins sold 8,120 shares of the stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $19.00, for a total value of $154,280.00. Following the sale, the insider owned 1,179,524 shares in the company, valued at approximately $22,410,956. This represents a 0.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 1,612,461 shares of company stock worth $27,754,413 over the last three months. 6.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several large investors have recently bought and sold shares of the business. Ameriprise Financial Inc. lifted its stake in Adaptive Biotechnologies by 84.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after acquiring an additional 2,731,648 shares during the period. Geode Capital Management LLC raised its holdings in shares of Adaptive Biotechnologies by 15.6% during the second quarter. Geode Capital Management LLC now owns 3,215,171 shares of the company’s stock valued at $37,461,000 after purchasing an additional 434,347 shares during the last quarter. Aristotle Atlantic Partners LLC lifted its position in Adaptive Biotechnologies by 8.6% during the third quarter. Aristotle Atlantic Partners LLC now owns 3,126,719 shares of the company’s stock valued at $46,776,000 after purchasing an additional 247,402 shares during the period. Jennison Associates LLC boosted its holdings in Adaptive Biotechnologies by 103.9% in the fourth quarter. Jennison Associates LLC now owns 2,674,668 shares of the company’s stock worth $43,437,000 after purchasing an additional 1,363,181 shares during the last quarter. Finally, Fred Alger Management LLC grew its position in Adaptive Biotechnologies by 6.7% in the 3rd quarter. Fred Alger Management LLC now owns 2,514,234 shares of the company’s stock worth $37,613,000 after purchasing an additional 158,807 shares during the period. 99.17% of the stock is currently owned by institutional investors.

More Adaptive Biotechnologies News

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Q4 results beat expectations — ADPT reported a $0.09 loss per share vs. a $0.19 consensus loss and revenue of $71.7M (up 51% YoY), which investors typically view as positive for growth outlook. Read More.
• Positive Sentiment: Analyst upgrade/target increase — JPMorgan raised its price target to $21 and maintained an overweight stance, implying meaningful upside versus recent levels and likely supporting buying interest. Read More.
• Neutral Sentiment: Multiple analyst write-ups and coverage: Zacks and other outlets published detail and comparisons to estimates; consensus remains a “Moderate Buy” with an average price target near the mid‑teens to low‑$20s — useful context but not a single catalyst. Read More.
• Neutral Sentiment: Full earnings materials and transcript are available for deeper review (management commentary and slide deck will guide whether revenue quality and guidance justify the rally). Read More.
• Negative Sentiment: Significant insider selling disclosed this week — CEO Chad M. Robins and other insiders sold large blocks (CEO ~125k shares; other insider sales also reported). Large insider sales can pressure sentiment even when results are strong. Read More.
• Negative Sentiment: Company remains unprofitable with negative margins and a negative ROE; analysts still expect a full-year loss (consensus EPS negative), which leaves valuation and timing of profitability as ongoing investor concerns. Read More.
• Neutral Sentiment: Reported short-interest data in this batch is effectively zero/unchanged and shows no immediate short‑squeeze dynamics; days‑to‑cover computed as 0.0, so short interest is not a current market driver. (Item flagged in recent data feeds.)

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.